Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus UTICILLIN VK.
PENICILLIN-2 vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic